Healthcare / Drug Manufacturers - Specialty & GenericBSE
$58.94
+2.80 (+4.99%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $4.0M · quality 54.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$148M
P/E
30.1x
↑EV/EBITDA
16.5x
↑ROE
5.2%
↑Gross Margin
68.0%
↑Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-2.2%
FCF CAGR
—
FCF margin
-26.3%
FCF / Net income
-3.45x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $65.3M · net income $5.0M · FCF $-17.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $65.3M | $65.3M | $70.3M | $71.5M | $69.7M |
| Net Income | $5.0M | $5.0M | $4.9M | $4.5M | $3.4M |
| EBITDA | $7.9M | $7.9M | $8.2M | $7.8M | $7.6M |
| EPS | 1.97 | 1.97 | 1.93 | 1.82 | 0.74 |
| Gross Margin | 68.0% | 68.0% | 67.1% | 64.8% | 62.5% |
| Operating Margin | 5.6% | 5.6% | 5.9% | 7.0% | 5.5% |
| Net Margin | 7.6% | 7.6% | 6.9% | 6.3% | 4.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.07 | 0.07 | 0.06 | 0.03 | 0.06 |
| Current Ratio | 3.93 | 3.93 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-17.2M | $-17.2M | $10.3M | $4.0M | $4.3M |
| Returns | |||||
| ROE | 5.2% | 5.2% | 5.4% | 5.5% | 4.4% |
| Valuation | |||||
| P/E | 30.07 | 30.07 | 21.91 | 20.98 | 37.91 |
| EV/EBITDA | 16.52 | 16.52 | 10.13 | 9.97 | 14.87 |
| P/B | 1.57 | 1.57 | 1.19 | 1.16 | 1.67 |
| Growth & Yield | |||||
| Revenue Growth | -7.1% | -7.1% | -1.8% | 2.6% | — |
| EPS Growth | 2.1% | 2.1% | 6.0% | 145.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
38.5%
EPS terminal req.
$5.23
Spread vs growth
-36.4%
5Y implied EPS CAGR
26.3%
EPS terminal req.
$6.33
Spread vs growth
-24.2%
10Y implied EPS CAGR
17.9%
EPS terminal req.
$10.19
Spread vs growth
-15.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-1.8%
Start / end P/E
31.1x → 29.9x
EPS bridge
1.93 → 1.97
Residual
-0.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.